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Otolin-1 is a collagenous, C1q domain-containing extracellular matrix protein that
has been identified and characterized in the inner ear. Recently, mass spectrometry
analysis of left ventricular cardiac tissue detected a peptide of Otolin-1. Experimental
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OTOLIN-1: AN INTRODUCTION

1.1

Otolin-1 is discovered in the extracellular matrix of the heart
The extracellular matrix (ECM) of the heart is a structural scaffold for cell

adhesion and migration and may regulate cell growth, metabolism, and differentiation.
The components of this matrix are arranged in intricate fibrillar, three-dimensional
structural units that are not easily solubilized or dissociated into singular proteins, which
makes the study of these individual components difficult. In order to better characterize
the cardiac ECM, de Castro Brás and colleagues developed a decellularization protocol to
enrich low abundance ECM proteins in the murine left ventricle (LV) and solublilization
and deglycosylation of these components for proteomic analysis [1].
Analysis by mass spectrometry of the decellularized ECM detected a peptide with
the sequence GDPGASGAHGFIGEPGAKGEKGGVGEKGYRGD. This peptide was
mapped to the 36 kilodalton (kDa) murine Otolin-1 protein, as illustrated in Figure 3.1. A
search of the peptide sequence using Blast software (NIH) to determine homology
yielded 100% identity to murine Otolin-1, 64% identity to murine Collagen XIII, 61%
homology to murine Collagen VI, 58% identity to murine Collagen XVIII, and 56%
identity to Collagen XXV, among others. Otolin-1 has not been characterized in the
myocardium to date; however, the protein has been extensively studied in the inner ear of
1

teleost fish and mice models. Following is a brief summation of the characterization of
the structure and function of Otolin-1 as observed in the inner ear.
1.2

The function of Otolin-1 as characterized in the inner ear.
The mammalian inner ear is a complex sensory organ responsible for the senses

of balance, detection of acceleration, and hearing. Though comprised of a closed
epithelial layer, the sensory epithelium of the inner ear is composed of several highly
diversified regions in respect to structure and function. The inner ear can be divided into
two main functional regions: the vestibular portion of the ear is responsible for sensing
motion and position, while the auditory or cochlear portion detects sound [2]. The
vestibular region of the ear contains 5 sensorial organs that can further be subdivided into
two categories based on functional differences; the three semi-circular canals (anterior,
horizontal, and posterior) detect head rotation, while the utricle and saccule sense linear
acceleration [3]. All are hair cell containing mechanoreceptors and function in much the
same manner. When stimulated, either by sound or motion, the specialized sensory
epithelium is moved in relation to regionally-specific acellular matrices, triggering the
sensory hair cell stereocilia to shift. This change in position of the stereocilia facilitates
the opening of mechanotransduction channels, and cell depolarization occurs, generating
electrical activity that can be processed by neurons in the brain [2, 4].
Only the utricle and saccule contain exceedingly dense matrices, known as the
otoconial complex. This concentrated matrix provides inertial mass that generates
shearing forces crucial for the macular mechanoreceptors to detect gravity and linear
acceleration [4]. Biomineralized calcium carbonate (CaCO3) crystals, called otoliths or
ear stones in teleost fish and otoconia or ear dust in mammals, are accountable for the
2

increased sensitivity to gravity and linear acceleration, due to the compact molecular
structure of calcium carbonate. These crystals are composed mostly of surface calcium
carbonate deposited around a small inner core of organic matrix [5], composed of
glycoproteins (otoconins) and proteoglycans [3]. Three polymorphisms of the crystals
have been discovered: calcite, found in mammals and birds; aragonite, found in
amphibians and fish; and vaterite, found in primitive jawfish. Differences in the
polymorphisms are attributed to the different major matrix protein component of the
organic core; mammals and birds contain Otoconin 90 as their primary matric protein,
amphibians contain Otoconin 22, primitive jawfish contain Otoconin 54, and teleost fish
contain otolith matrix protein (Omp) [3].
Formation of these crystals occurs during embryonic development; while otoconia
are developed beginning in late embryonic stages and mature shortly after birth, otoliths
display a daily growth pattern [6]. These are the only tissue formations of calcium
carbonate found within the body and are localized to the inner ear; bones, teeth, and
scales are composed of calcium phosphate [5, 7]. Otoconia (otoliths) rest atop and are
anchored to the otoconial (otolithic) membrane, a gelatinous layer containing meshworklike collagens that connects to the sensory epithelium, known as the maculae [3]. The
organic matrix that forms the foundation of the calcium carbonate structures is dependent
on the organism in which the crystals are found and is responsible for calcium carbonate
mineralization. Mice share similar otoconia and inner ear properties with humans [6], and
murine otoconia have been well characterized. The otoconial matrix of mice is comprised
mainly of soluble Otoconin 90, with minor otoconins being Otolin-1, Osteopontin,
Fetuin-A (or countertryptin), Sparc-like 1 (secreted protein acidic and rich in cysteine,
3

also Sc1 or hevin), cerebellin-1, and possibly Sparc, DMP1 (dentin matrix protein) and αtectorin, and the proteoglycan keratin sulfate proteoglycan [3, 6, 8].
Otolin-1 was first characterized as an inner ear collagenous protein in chum
salmon otoliths by Murayama and colleagues and has been characterized in teleost fish
and murine models. mRNA expression for Otolin-1 is limited to the inner ear [3, 5], and
the protein is synthesized, secreted apically from the epithelium into the endolymph, and
incorporated into the otoconia/otolith and gelatinous layer of the otoconial/otolithic
membrane [9]. The major otoconin (Otoconin 90 in mice, otolith matrix protein in teleost
fish) is responsible for recruiting Otolin-1 to the site of the otoconia [10], and these
proteins form the basis of the otoconial/otolithic framework and are responsible for the
sequestration of Ca2+ in the extracellular matrix for calcification of the structure [8].
Otolin-1 binds together with other otoconins to form high molecular weight aggregates
which are responsible for the ring-like architecture of the otoconia/otolith and crystal
morphology [11]. Otolin-1 is also found in fine fibrils interconnecting adjacent otoconia
in mice, which makes use of the high tensile strength of collagenous molecules,
necessary due to the continuous movement between otoconia during mass movements of
the complex [7]. Otolin-1 is responsible for anchoring the otoconia/otolith to the
otoconial/otolithic membrane and stabilizing the organic matrix by providing a
collagenous scaffold [10].
The Otolin-1 gene in mice is approximately 21 Kb in size and located on
chromosome 3E12. Consisting of 5 exons and 4 introns, comparison to the human gene
reveals the exon/intron structure is Otolin-1 is conserved between the species. The
translated Otolin-1 protein is 482 amino acids in length, and contains a signal peptide, a
4

collagen domain with 74 Gly-X-Y repeats, and a C-terminus globular domain
homologous to the immune compliment C1q, making Otolin-1 a new member of the
C1qTNF protein family. Another name for Otolin-1 is C1QTNF15, or C1q and Tumor
Necrosis Factor Related Protein 15. The C1q globular domain is thought to play a
significant functional role in interactions with other proteins and receptors. All members
of the C1q/TNF protein family form a trimer as their basic structural unit, with some
trimmers further assembling into higher order structures; Otolin-1 has the ability to form
higher order multimeric complexes [3].
Otolin-1 has several posttranslational modifications, not unlike many proteins
with collagen domains to enhance the stability of their triple helical collagen structure.
Mouse Otolin-1 also contains 10 proline residues that are potential sites for hydroxylation
and 44 lysine resides for potential hydroxylation and glycosylation sites. Mass
spectrometry analysis found 9 of the 10 proline residues to be hydroxylated and only 2 of
the 44 lysine residues were hydroxylated and glycosylated with a glucosyl-galactosyl
group. The other lysine containing peptides were too small for detection, and their
posttranslational modification status remains unclear [3]. This high level of glycosylation
allows Otolin-1 to bind calcium carbonate without structural damage to the collagenous
triple helix; while modeling shows that calcium carbonate leads to increased unfolding of
the triple helix by aggregating within the collagen backbone, the glycosylation sites on
Otolin-1 offer favorable association sites for carbonate ions, protection the triple helix
from obliteration [12].
Otolin-1 shares a high homology with type X collagen, which also belongs to the
C1q family of proteins. Type X collagen is a non-fibrillar short chain collagen found in
5

hypertrophic chondrocytes, which oligomerizes supramolecularly into a threedimensional, hexagonally arranged lattice. The collagenous domain of Otolin-1 is almost
half that of type X collagen, suggesting that the lattice size in the otoconia/otolith is
smaller than that in the hypertrophic chondrocytes [10]. Otolin-1 has 74 Gly-X-Y repeats
and type X collagen contains 129 Gly-X-Y repeats in the collagen-like domain, where X
is usually Proline and Y hydroxyproline in collagen. The C-terminal globular C1q
domains of Otolin-1 and type X collagen share 68% amino acid sequence similarity.
Murine Otolin-1 and human type X collagen have similar tertiary structures and are
nearly superimposable [8].
1.3

Investigation of Otolin-1 in the myocardium
Detection of the peptide by mass spectrometry analysis in the LV led to my

investigation of the role of Otolin-1 in the heart. Immunoblotting and
immunohistochemistry were used to discover that Otolin-1 is an insoluble protein in the
cardiac extracellular matrix. Protein levels are affected during ECM reorganization postmyocardial infarction (MI), as Otolin-1 levels drop dramatically at day 5 post-MI. The
depletion of protein in the infarct tissue of the LV also correlates robustly with cardiac
end diastolic dimension, visualized with echocardiography.
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CHAPTER II
METHODS

Wild type C57BL/6J male and female mice, ages 3-6 months, were used for the
model for myocardial infarction (MI). MI was induced by coronary artery ligation.
2.1

Echocardiography
A baseline and terminal echocardiogram were taken for each mouse. The hair was

removed from the chest region using a topical cream remover (Nair), and the mice were
anesthetized using isoflurane. The mouse was then placed on the heated echo table in the
supine position, where a nose cone was attached to provide 2-2.5% isoflurane and oxygen
at a 0.8-1.0 mL/minute flow rate. Electrode gel was placed on all four paws before
securing the paws to the ECG electrodes with tape.
The probe was used to check left ventricular long axis, then a foam support was
taped to the right side of the mouse before tilting the table to the left to best position the
mouse for the ECG. Ultrasound gel was placed on the chest of the mouse and used to
lubricate the rectal probe responsible for monitoring body temperature. Once body
temperature was stabilized to 36 degrees C (give or take one degree) and the heart rate
was measured to be 400 beats per minute or greater (for physiological relevance),
echocardiography could begin.
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The long axis view of the left ventricle was acquired by aligning the probe until
the papillary and aortic outflow were clearly displayed with the maximum left ventricular
chamber, aligning the apex and aorta along the horizontal plane. The apex appeared to the
left of the image, and the aorta was found on the right. Once the alignment was
configured, the echocardiography was recorded. The short axis view was acquired by
rotating the probe ninety degrees clockwise from the long axis view. The papillary was
visualized at 2 o’clock and 4 o’clock positions to ensure proper alignment before
recording. After the echocardiography was performed, the gel was removed, the paws
released, and the nose cone supplying the anesthetic disconnected. The mouse was
monitored during recovery and returned to cage once normal breathing patterns were
established.
2.2

Infarct surgery
Coronary artery ligation was performed as described by Zampila and colleagues

[13]. Before the surgery, the mouse was placed in the isoflurane box until anesthetized.
The mouse was then moved to the heated surgical board, where an anesthetic nose cone
was placed over the face of the mouse. Isoflurane was administered at 2% in a 100%
oxygen mix to maintain unconsciousness. Placed in a supine position, the paws and base
of the tail were taped to the surgical board to secure the mouse. A cream depilatory was
applied to the thorax and neck to remove hair, and the area was sanitized with gauze
containing 70% ethanol. An injection of buprenorphine at 0.1 mg/kg was administered
intraperitoneally.
A longitudinal incision of 1 cm was made on the ventral midline of the neck to
expose the submandibular glands. Blunt dissection was used to expose the sternothyroid
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muscles, which were retracted laterally in order to view the ventral aspect of the trachea.
Removing the nosecone, a 10-15 cm piece of string was looped around the upper incisors,
and gentle traction was applied cranially to ensure an open and straight airway. Lifting
the tongue with forceps, the mouse was intubated by guiding a 20 gauge IV catheter into
the trachea, using a blunted IV catheter needle as support. This step was monitored with a
microscope to ensure clear passage of the tube. The catheter was advanced until the tip
was visualized within the trachea through the incision at the neck. Once intubated, the
support needle was removed and the catheter was connected to the anesthesia tubing from
the nose cone. Isoflurane levels were adjusted to 2%, and the stroke volume and rate were
adjusted based on mouse size, starting at 225-250.
After cutting a 1cm square strip of gauze soaked in saline, the mouse was rotated
to expose the left parasternal area. An incision 1 to 1.5 cm in length was made
transversally at the mid-thorax, starting left of the ventral midline and extending laterally.
This cut was parallel to the ribs and approximately 2 cm below the left axilla. Blunt
dissection was used to expose the left pectoralis major muscles. A 3-0 retention suture
was placed around the muscles to retract them toward the right shoulder of the mouse,
exposing the rib cage. An additional 3-0 retention suture was placed around the left rectus
thoracis and serratus ventralis muscles. These muscles were retracted towards the left
side of the mouse, and the retention suture was affixed to the surgical board with tape as
close to the body of the mouse as possible. The muscle striations were bluntly dissected
at the intercostal space between the third and fourth ribs to make a 0.25 cm incision,
which penetrated into the thoracic cavity. Saline-soaked gauze was placed into the
thoracic incision and pushed gently toward the lungs, avoiding damage to the organs. The
9

thoracic incision was enlarged slowly to approximately 1 cm long by blunt dissection
applied medially and laterally while using the gauze to protect the lungs. The miniGoldstein retractor was applied to the incision, and the ribs were gently spread to
visualize the left atrium and ventricle. Fine forceps were used to remove the pericardium
and provided access to left ventricular free wall for identification of the left anterior
descending coronary artery.
The atrium was moved up using a small piece of gauze. An 8-0 suture, stabilized
by a Castroviejo needle holder, was guided under the coronary artery 1 mm distal to the
left atrium and ligated securely with a square knot. Suture was knotted twice to ensure
ligation. Discrete blanched region was confirmed on the LV with a microscope. The rib
retractor was removed, and a 6-0 suture was placed to encircle the outer edges of the
separated ribs. The gauze was removed, and the knot was secured to the ribs, which were
repositioned in the chest and the incision was closed. The retracted muscle layers of the
chest were repositioned after removal of the retention sutures. The thoracic and neck
incisions were closed with a 6-0 suture. Tape was removed and isoflurane was stopped,
but the oxygen was maintained. The mouse was moved to a prone position and extubated.
The mouse was checked for spontaneous breathing immediately after removal of
intubation tube and left on heated platform with oxygen until consciousness was
regained.
2.3

Tissue Harvesting
Terminal echocardiography was performed on the mice before harvesting the left

ventricle. After the echocardiography was acquired, the mouse was moved to the heated
surgery board, where the animal was anesthetized with isoflurane via nose cone and
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secured to the platform in the same fashion as the ligation surgery. Once sedated and
positioned, the mouse was injected with heparin intraperitoneally (4 units/gram body
weight) and allowed to rest for 5 min. After an incision was made at the thorax, the
carotid artery was exposed and severed to collect blood. The blood was immediately spun
down for 5 min to separate, and the plasma was collected, snap frozen in liquid nitrogen,
and stored at -80 degrees C.
Incisions were made in the abdomen following the ribcage, opening the abdomen
to visualize the heart and lungs. Cardioplegic solution was injected into the apex of the
heart, which was flushed and arrested in diastole. The heart and lungs were excised,
separated, and placed in cardioplegic solution. The right and left lungs were separated.
The atria were removed from the ventricles, and the right ventricle was detached from the
left ventricle, which was cleaned and sectioned transversely into apex, middle, and base
regions. The lungs and ventricles were weighted and recorded. The lungs were set to dry
in an incubator, and the ventricles were stained with 2,3,5-triphenyltetrazolium chloride
(TTC) for 5 min at 38 degrees C and photographed. The right ventricle was discarded,
while the apex and base were snap frozen in liquid nitrogen and stored at -80 C. The
middle section was fixed in zinc-formalin at room temperature for 24 h before being
stored in 70% ethanol at 4 degrees C for histological use. The left hind limb was removed
and placed in NaOH for 24 h to remove tissue, from which the tibia was removed and
measured. The dried lungs were weighed and recorded.
2.4

Protein Extraction
The LV samples were weighed, and a solution of PBS (Invitrogen) and protease

inhibitor cocktail, or PI (company) was added, 16 µL of buffer for every mg LV, with a
11

volume no less than 250 µL. The samples were homogenized using the PowerGen 1000
(Fisher) until no visible tissue was observed.
The homogenate was then transferred to a 1.5 mL tube (Eppendorf), one tube per
sample. The samples were centrifuged at 4700 rpm for 10 min at 4 degrees C. After
centrifugation, the soluble protein supernatant was removed to a new 1.5 mL tube. The
insoluble protein pellet was washed three times with PBS, using the same volume as the
fractionation buffer, and centrifuged for 5 min following.
After the washes, a solution of PI and Reagent 4 (Sigma) was added to the pellet
in equal volume to the solution of PBS. The samples were vigorously vortexed then
homogenized again, slowly, until completely dissolved. The tubes were then covered and
centrifuged at 3000 rpm for 2 min at 4 degrees C to reduce the foam on top. The soluble
fraction was transferred to a fresh 1.5 mL tube.
2.5

Protein Quantification
Protein levels were then quantified for the soluble and insoluble fractions. For the

soluble protein fraction, samples were diluted 1:10 with a mixture of PI diluted 1x in
PBS; the insoluble fraction was diluted 1:40 to compensate for the R4. Bovine Serum
Albumin standards were created, with final concentrations of 1.0, 0.8, 0.5, 0.3, 0.2, 0.1,
and 0.05 μg/μL solutions of BSA in PBS/PI for the insoluble fraction, and BSA in
PBS/PI with R4. 10 µL of each standard and each sample were transferred in triplicate to
a 96-well plate. 200 µl of Biorad Bradford dye was added to each well, and the plate was
incubated for 5 min at room temperature on a shaker. The plate was then put into the
reader, and the results were read at A-595 wavelength.
12

2.6
2.6.1

Immunoblotting
Electrophoresis
Samples were prepared for western blotting by thawing at 30 degrees C for at

least 30 min and spun down. 10 µg of the homogenized tissue was removed and added to
a separate 1.5 mL tube with distilled water and loading dye to equal 18 µL, then
subsequently vortexed and centrifuged. The samples were heated to 95 degrees C for 5
min before being vortexed and centrifuged a second time. 15 µL of each sample and 5 µL
of molecular weight marker (Kaleidoscope Precision Plus MW Standard, Biorad) were
then loaded into a 24 well 4-12% bis-tris gel (Biorad) with XT MES electrophoresis
buffer (Biorad). The gel was run at 25 V until the samples were past the stacking gel,
then the voltage was increased to 180 V to run the samples all the way through the gel.
2.6.2

Transfer
The gel was transferred to a nitrocellulose membrane (Biorad) using chilled

Tris/Glycine transfer buffer (Biorad) with methanol. The gel was run at 65 V for 1 h 30
min.
2.6.3

Total protein stain
After transfer, the gel was trimmed to size and washed in distilled water for 5

min. The membrane was then placed in Pierce Reversible Protein Stain (Thermo
Scientific) and shaken for 45 sec. The stain was then removed, and the membrane was
rinsed with Pierce Destain for 30 sec with shaking. The membrane was removed from the
destain and rinsed in distilled water before being imaged (ImageQuant, GE). The
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membrane was washed with Pierce Eraser until clear, approximately 5 min, and rinsed
with distilled water.
2.6.4

Blocking
A blocking solution of 5% w/v nonfat milk (Biorad) in TPBS (0.1% Tween in

PBS) was prepared ahead of time, at least one h before use. The membrane was covered
with the milk solution and set to shake for one h at room temperature.
2.6.5

Primary Antibody
The Otolin-1 primary antibody (Sigma HPA041030) was diluted 1:1000 in the

5% milk solution. The membrane and primary antibody were sealed in a plastic pouch
and incubated overnight, approximately 16 h, at 4 degrees C on a rocker at maximum
speed. After the incubation period, the primary antibody was discarded and the
membrane was washed 3 times in TPBS for five min each.
2.6.6

Secondary Antibody
The rabbit secondary (Vector PI-1000) was diluted 1:5000 in the 5% milk

solution and incubated on the membrane in a plastic pouch for 1 h at room temperature,
rocking at maximum speed. The secondary antibody was then poured off, and the
membrane was washed for 5 min in TPBS three times with agitation.
2.6.7

Chemiluminescence
The ECL (Amersham) chemiluminescence was mixed in equal parts and allowed

to incubate while reaching room temperature. Excess TPBS was blotted from the
membrane, and the solution was poured over the membrane to completely and uniformly
cover the surface. The membrane was incubated for 5 minutes, blotted of excess
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substrate, and placed on the plate for development (ImageQuant LAS 4000, GE). Images
were taken after 1 or 2 sec exposure times. After exposure, the membrane was sealed in
a plastic pouch with 1x PBS and stored at 4 degrees C.
2.6.8

Image analysis
Images were analyzed with ImagequantTE software (GE), where the exposed

bands were quantified. The bands were then first normalized to total protein level for that
lane to determine protein expression relative to that sample, reducing loading error
effects. Individual blots were then normalized together by using two ratios: the first was a
ratio of the total proteins of each blot to account for inconsistencies in Pierce staining,
while the second was a ratio of the uniform molecular marker to account for
inconsistencies in camera readings of the individual blots. The normalized data from the
three blots were then used, where statistical analysis was then performed on the data.
2.7

Immunohistochemistry
Slides were made using formalin- fixed tissue embedded in paraffin, sectioned 5

microns thick and mounted to slides by AML Laboratories. The paraffin embedded slides
were rehydrated by deparaffinizing in Citrisolv twice 10 min each, followed by a pair of
5 min washes in each of the following dilutions: 200 proof ethanol, 190 proof ethanol,
and 140 proof ethanol. Following a 5 min wash in distilled water, the slides were heated
in a 1x solution of Dako Antigen Retrieval to right under boiling for 15 min. After
cooling, the slides were washed with distilled water three times in 5 min intervals before
being incubated with 3% hydrogen peroxide for 20 min, followed by two 5 min washes in
distilled water and one 5 min wash in 1x PBS. The samples were then blocked for 20 min
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using Vectastain Elite ABC kit (anti-rabbit for the Otolin-1 and Connexin-43 antibodies,
anti-rat kit was used for the Neutrophil and Mac-3 antibodies) before adding the primary
antibody: Otolin-1 (Sigma HPA041030), Neutrophil (Cedarlane CL8993AP), and Mac-3
(Cedarlane CL8943AP) at a 1:100 dilution; Connexin-43 (Sigma C6219) at a dilution of
1:1000. Slides were allowed to incubate overnight at 4 degrees C.
After the slides were incubated and allowed to return to room temperature, three
washes followed in PBS for 5 min each. Secondary antibody from the ABC kit was then
applied, and the slides incubated for 30 min under agitation. Another stage of 5 min
washes in PBS was performed, and then the slides were placed in ABC reagent for 30
min. After subsequent washing, the slides were incubated in HistoMark BLACK for 5
min, or until strong staining was evident. The reaction was halted by distilled water, and
the slides were counterstained with eosin and washed again in distilled water.
Slides were dehydrated by washes in 190 proof ethanol for 15 sec, 190 proof
ethanol for 30 sec, two washes in 200 proof ethanol for one min each, a wash in Citrisolv
for 2 min, and finally a five min wash in Citrisolv before coverslipped with mounting
medium and imaged using microscope. Images were captured at 20x and 40x
magnifications.
2.8

Statistical analysis
Multiple group comparisons were analyzed by one-way analysis of variance

(ANOVA), followed by the Student–Newman–Keuls when the Bartlett's variation test
passed. Two group comparisons were analyzed using the unpaired t test. Data was
presented as mean ± SEM. Regression analysis was performed on comparisons of
16

echocardiography and Otolin-1 data. All statistical analysis was performed using
GraphPad InStat and Prism software. P < 0.05 was considered statistically significant.
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CHAPTER III
RESULTS

3.1

Otolin-1 is an insoluble protein present in the LV
Mass spectrometry analysis of extracellular matrix components from the left

ventricle of the heart from previous study [1] detected a peptide in the insoluble protein
fraction mapping to Otolin-1, as seen in Figure 3.1.

Figure 3.1

A peptide sequence GDPGASGAHGFIGEPGAKGEKGGVGEKGYRGD
was identified by mass spectrometry analysis of left ventricular tissue,
which corresponds to the collagen domain of the murine Otolin-1 protein.

To determine whether Otolin-1 could be detected by western blotting in the LV
tissue, a blot was performed using day 5 post-MI tissue (to coincide with the mass
spectrometry samples) as well as uninfarcted tissue for a control. Immunoblotting of
soluble and insoluble protein fractions of the LV in normal cardiac tissue and at day 5
post-MI reveals Otolin-1 protein is indeed present in the LV, but appears only in the
insoluble protein fraction (Figure 3.2). This is consistent with data previously published
18

by Murayama and colleagues [5]. A single band appears in the blot at approximately 36
kDa. Moreover, in the insoluble fraction, Otolin-1 is present in normal LV tissue but is
greatly decreased at day 5 post-MI, appearing to be absent. This change in intensity
indicates that cardiac remodeling post-MI affects levels of otolin-1 in the LV.

Figure 3.2

Immunoblotting of left ventricular tissue protein reveals Otolin-1 is present
in the insoluble fraction in un-infarcted tissue but disappears at day 5 postMI, indicating an MI effect on Otolin-1.

Immunoblotting of left ventricular tissue protein reveals Otolin-1 is present in the
insoluble fraction in un-infarcted tissue but disappears at day 5 post-MI, indicating an MI
effect on Otolin-1.

3.2

Otolin-1 levels decrease dramatically post-MI
Noting the differences in protein expression between normal tissue and 5 days

post-MI, a post-MI time course evaluation was performed. Immunoblotting a time course
of the insoluble LV protein fraction of normal LV tissue and tissue from days 1, 3, 5, and
7 post-MI reveals that Otolin-1 expression is highest in normal tissue and decreases
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following MI in both the remote (LVC) and infarct (LVI) regions of the LV (Figure 3.3).
Otolin-1 is significantly decreased in the infarct at days 5 and 7 post-MI in comparison to
levels at day 0, with day 0 levels 3 fold higher than LVI protein expression at day 5 postMI. A direct comparison of day 0 and day 5 LVI highlights the extreme differences in
protein expression between the two time points (Figure 3.4).

Figure 3.3

A time course of Otolin-1 pre- and post-MI reveals that Otolin-1 is
expressed at approximately 36 kDa in the left ventricle and decreases with
time in both the infarct and remote/control regions.

Significant depletion of the protein occurs in the infarct at days 5 and 7 post-MI, when
compared to pre-MI and day 1 post-MI levels (p<0.05 for both groups). Each group is
comprised of n=8 biological replicates pooled and run in n=3 technical replicates. Data
are shown as mean ± SEM.

20

Figure 3.4

A comparison of un-operated and day 5 post-MI LVs illustrates the drastic
disparity in Otolin-1 levels.

Biological replicates of n=8 were used for each group, and a significance of p=0.0002
was observed. Data are shown as mean ± SEM.

3.3

Immunohistochemistry may point to function of otolin-1 in LV
Having confirmed the presence of the protein in the LV, information about the

localization of Otolin-1 in the LV is needed to characterize the protein, especially the role
Otolin-1 plays in the myocardium. Otolin-1 immunohistochemistry was performed in a
time course like that of the immunoblotting and supports the immunoblot data, showing
an abundance of Otolin-1 at day 0 in the LV and decreasing markedly in the LVI at days
5 and 7 post-MI. In the LV, Otolin-1 staining is restricted to regions containing
myocytes. Serial sections reveal that Otolin-1 staining is evident in the viable
myocardium but depleted in necrotic tissue, as evidenced in the comparison of Otolin-1
and Hematoxylin and Eosin (H&E) staining (Figure 3.5).
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Figure 3.5

Immunohistochemistry of Otolin-1 in normal myocardium (Day 0) and at
day 5 post-MI.

Otolin-1 staining is present in the living myocardium, but staining is significantly
decreased in infarcted tissue. Images are presented at 20x magnification.

Eosin was used as a negative control to verify Otolin-1 staining in the myocytes
(Figure 3.6). A banding pattern is observed in the remote regions of the LV, with Otolin1 seeming to appear at the myocyte junctions, indicating that Otolin-1 may be a
component of the cardiac ECM. This staining is diminished in the infarct region, limited
to viable myocytes and failing to be observed in the necrotic tissue.
To confirm that Otolin-1 was staining at the gap junctions, immunohistochemistry
of Connexin 43 was performed for verification of location. Serial sections stained with
Otolin-1 and Connexin 43, respectively, show similar patterns (Figure 3.7). Connexin 43
is located within the gap junctions of cardiomyocytes, having both intra- and extracellular
domains [14] and is the most abundant connexin in the mammalian ventricular
myocardium [15]. Comparisons of serial sections show staining commonality of Otolin-1
and Connexin 43, which suggests protein colocalization within the gap junctions of the
myocytes and possible ECM function for Otolin-1.
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Figure 3.6

Otolin-1 immunohistochemistry staining in the remote, border, and infarct
regions of the LV.

Serial sections are stained with Eosin to show differential staining in the Otolin-1 slides.
Images are shown at 40x magnification.

Figure 3.7

Immunohistochemistry of Otolin-1 and Connexin 43 performed on serial
sections show remarkable similarity in staining, indicating colocalization of
the proteins.

Connexin 43 is known to reside in the gap junctions of the myocytes, placing Otolin-1 in
the cardiac ECM. Images are shown at 40x magnification.
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3.4

Otolin-1 and cardiac matrix remodeling
Post-MI, the LV undergoes extensive remodeling. Changes in the extracellular

matrix are influenced by this remodeling process. In the acute phase of remodeling,
neutrophils are present early on, noticeably at days 1 and 3 post-MI. Serial sections for
Otolin-1 and neutrophils show no clear correlation, indicating that neutrophils are not
responsible for the drastic changes in LV protein expression post-MI (Figure 3.8).

Figure 3.8

Immunohistochemistry of Otolin-1 and neutrophils at day 1 post-MI
performed on serial sections indicate no remarkable correlation exists
between Otolin-1 and neutrophils.

Images are shown at 20x and 40x magnifications.
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During the cardiac remodeling process, neutrophils recruit macrophages, which
infiltrate the LVI and break down the necrotic tissue and surrounding ECM.
Macrophages are evidently abundant at days 5 and 7 post-MI. Serial sections stained for
Otolin-1 and macrophage presence show that Otolin-1 and macrophages do not occupy
the same space; while macrophages localize to the infarcted tissue, Otolin-1 stains the
remote, viable myocardium (Figure 3.9). These findings indicate that macrophage
debridement of necrotic myocytes and surrounding ECM may be responsible for the
depletion of Otolin-1 expression in the LVI.
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Figure 3.9

Immunohistochemistry of Otolin-1 and macrophages at day 7 post-MI
performed on serial sections show intense segregation of staining at the
border zone of the infarct region.

Otolin-1 staining is relegated to the remote regions, while macrophages are abundant in
the infarct. Images are shown at 20x and 40x magnifications.

3.5

Otolin-1 LV protein levels are inversely correlated with end diastolic
dimension post-MI
Since Otolin-1 is depleted in the infarct region post-MI and is localized with

myocyte ECM, echocardiography was used to determine if the lack of Otolin-1 in the
infarct was linked to ventricular dysfunction. Otolin-1 protein levels at D0 and in the LVI
post-MI were compared to end diastolic dimension (EDD). The amount of Otolin-1 in
each sample was compared to the EDD for the same animal. Since the immunoblot
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samples were pooled, the average protein level of the infarct region for the post-MI time
course was matched to the average EDD for each day and plotted as a scatter plot (Figure
3.10). The data exhibited a linear trend with a negative correlation; as the level of Otolin1 decreased, EDD increased. The correlation has an r squared value of 0.77 and
p=0.0496.

Figure 3.10

Comparisons of end diastolic dimension to Otolin-1 levels throughout the
MI time course reveal an inverse correlation between ventricular dimension
and the amount of protein in the LVI.

As Otolin-1 levels decrease in the infarct region, EDD becomes larger. An r squared of
0.77 is observed, with p=0.0496. Data are shown as mean ± SEM.

Individual plots were made for day 0 and day 5 post-MI, where each individual
was matched with its respective EDD and Otolin-1 protein level (Figure 3.11). Day 0
showed no significant correlation between protein level and EDD. At day 5 post-MI,
protein levels in the LVI were plotted against EDD and shown to have a strong negative
correlation, with an r squared value of 0.92 and p=0.0002.
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Figure 3.11

Individual comparisons of Otolin-1 levels to EDD in normal tissue (left)
and in infarcted tissue at day 5 post-MI (right) reveal that, while no
correlation is evident at day 0, day 5 shows a strong negative linear
correlation between protein levels and EDD, with an r squared of 0.92 and
p=0.0002.

Due to the high linearity between Otolin-1 protein levels in the LVI and EDD at
day 5 post-MI, other echocardiography parameters were also tested for correlations. End
systolic dimension (ESD) and fractional shortening were compared to Otolin-1 in the
same manner as EDD, as shown in Figure 3.12. ESD at day 5 post-MI was shown to have
a negative linear correlation with Otolin-1 levels in the infarct region, with an r squared
of 0.8599 and p=0.0009. However, fractional shortening did not correlate with Otolin-1
levels; this is surprising, considering fractional shortening is derived from EDD and ESD.
One explanation for this is the presence of an outlier; this animal also has a smaller
infarct area, which could affect fractional shortening. Echocardiography data can be
visualized in Figure 3.12.
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Figure 3.12

Comparison of end systolic dimension (left) and fractional shortening
(right) to Otolin-1 infarct levels at day 5 post-MI reveals a negative linear
correlation between ESD, with an r squared value of 0.8599 and p=0.0009,
similar to comparisons of Otolin-1 and EDD at day 5 post-MI.

However, fractional shortening, which is the percent change between EDD and ESD, was
not shown to correlate significantly with Otolin-1 levels in the LVI.
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CHAPTER IV
DISCUSSION

4.1

Otolin-1 in the myocardium
Otolin-1 is an insoluble extracellular matrix protein found in the normal

myocardium, visualized with IHC at the gap junctions between myocytes in the left
ventricle. Post-MI, levels decrease significantly and show a strong association with LV
aneurysm, which indicates that post-MI ventricular remodeling has a large effect on
Otolin-1 protein levels in the myocardium.
4.2

Cardiac remodeling of the extracellular matrix in the left ventricle postmyocardial infarction, and how Otolin-1 may play a part
The cardiac extracellular matrix (ECM) is comprised of numerous protein

components, estimated to include upwards of 140 individual protein constituents [16]. Of
these proteins, several have shown involvement in LV remodeling post-MI. The ECM is
made up of several types of proteins; components include: structural proteins such as
collagens, laminins, and fibronectin; matricellular proteins such as SPARC and
thrombospondin-1; and matrix metalloproteinases (MMPs). This results of this study
indicate that Otolin-1 is also included in the cardiac ECM, and possibly functions as a
structural protein of the myocyte ECM.
During a myocardial infarction, the blood supply is cut off to the myocardium,
producing an ischemic event. When the ischemic event is prolonged enough to cause
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irreversible ischemic damage, affected regions of the myocardium will experience cell
death. The remodeling process involves a system of overlapping phases of inflammation,
wound granulation, wound contraction, and collagen deposition that lead to remodeling
of the infarcted LV [17].
The inflammatory process initiates LV remodeling by recruiting
polymorphonulcear granulocytes (PMNs or neutrophils) to the infarct, where chemokine
concentrations are high. In permanent occlusion models such as used in this study, PMNs
infiltrate the infarcted LV within hours, peak at days 1 through 3, and start to decline at
day 5 to very low presentation at day 7 in the acute post-MI timeline [18]. These PMNs
are responsible for releasing granular components, such as myeloperoxidase and MMPs,
as well as reactive oxygen species (ROS) for antimicrobial benefit and are initiators of
cardiac ECM remodeling. Otolin-1 levels are not greatly affected by PMN activity, as
there is no significant decrease in protein levels during PMN peak activation post-MI and
immunohistochemistry analysis does not show a strong correlation between Otolin-1
levels and the presence of PMNs.
Macrophages are recruited to the infarct via PMN signaling. Infiltration begins at
day 3 post-MI, where the macrophage is differentially activated to perform several
functions [17]. M1 macrophages promote inflammation and ECM deconstruction and are
the first pathway activated; M2 macrophages, activated later in the post-MI remodeling
process, are responsible for ECM construction, cell proliferation, and angiogenesis. The
main role of the macrophage is phagocytosis of apoptotic neutrophils and necrotic
myocytes, but other important functions include fibroblast activation and collagen scar
formation by regulating ECM turnover [19]. Fibroblasts activation occurs a day 3 post31

MI and coincides with macrophage activation. The fibroblasts are differentiated into
myofibroblasts, which synthesize and deposit collagen to help form the scar that replaces
the debrided myocytes [20]. Unlike PMNs, macrophages are directly involved in the
depletion of Otolin-1 in the LVI. M1 macrophages debride the necrotic myocytes, but
also destroy the ECM surrounding the dead cells in doing so. Otolin-1, having been
localized to the ECM of myocytes, is being degraded as a result of macrophage activity.
Exactly how the Otolin-1 is being removed remains unclear, as the specific mechanism
for depletion is not known.
Changes in the ECM of the LVI affect not only the infarct region but the LV as a
whole. Post-MI, the myocardium in the infarct region undergoes rapid changes, one of
which is wall thinning, which can be observed within hours of MI onset. The necrotic
tissue also exhibits decreased contractility, and the whole hemodynamic structure of the
LV is changed to compensate. The excess stress on the walls of the LV results in dilation
of both infarct and remote regions, increasing the dimensions of the LV and resulting in
ventricular aneurysm [21]. All of these changes can be visualized and measured using
echocardiography. Loss of Otolin-1 in the LVI has been shown to correlate with diastolic
and systolic dimensions of the LV at day 5 post-MI, when Otolin-1 levels are at their
lowest in the acute MI phase. However, Otolin-1 has not been shown to have a significant
correlation with fractional shortening, which is the percent change between systolic and
diastolic end dimensions.
4.3

Otolin-1 conclusions and future directions
Through a series of experimental procedures, Otolin-1 has been shown to be a

constituent of the normal ventricular ECM, possibly functioning as an insoluble structural
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protein. During the acute cardiac matrix remodeling process, macrophage mediated ECM
turnover and necrotic myocyte debridement results in a substantial loss of Otolin-1 in the
infarct region appreciable at day 5 post-MI. The loss of Otolin-1 expression in the infarct
can be correlated to LV dilation, though a causative link remains unclear. Though the
importance of Otolin-1 is not well understood in normal ECM, loss of protein expression
post-MI has been linked to LV dysfunction, indicating that the presence of Otolin-1 may
be indicative of proper ventricular function. Further investigation into the function of
Otolin-1 in the ECM may elucidate the connection between protein loss and LV dilation
post-MI.
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SUPPLEMENTAL DATA
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A.1

Otolin-1 time course
Otolin-1 and Eosin were stained in a MI time course to observe the changes in

protein expression and location. Representative images from days 0, 1, 3, 5, and 7 postMI are shown, with various images of remote and infarct regions selected (Figure A.1,
Error! Reference source not found., Figure A.3, Figure A.4, Figure A.5, Figure A.6,
and Figure A.7).

Figure A.1

Otolin-1 immunohistochemistry staining in normal LV.

Serial sections are stained with Otolin-1 and Eosin to show differential staining in the
Otolin-1 slide. Images are shown at 40x magnification.
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Figure A.2

Otolin-1 immunohistochemistry staining in the infarct region at day 1 postMI.

Serial sections are stained with Otolin-1 and Eosin to show differential staining in the
Otolin-1 slide. Images are shown at 40x magnification.

Figure A.3

Otolin-1 immunohistochemistry staining in the remote region at day 3 postMI.

Serial sections are stained with Otolin-1 and Eosin to show differential staining in the
Otolin-1 slide. Images are shown at 40x magnification.
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Figure A.4

Otolin-1 immunohistochemistry staining in the infarct region at day 3 postMI.

Serial sections are stained with Otolin-1 and Eosin to show differential staining in the
Otolin-1 slide. Images are shown at 40x magnification.

Figure A.5

Otolin-1 immunohistochemistry staining in the infarct region at day 5 postMI.

Serial sections are stained with Otolin-1 and Eosin to show differential staining in the
Otolin-1 slide. Images are shown at 40x magnification.
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Figure A.6

Otolin-1 immunohistochemistry staining in the remote region at day 5 postMI.

Serial sections are stained with Otolin-1 and Eosin to show differential staining in the
Otolin-1 slide. Images are shown at 40x magnification.

Figure A.7

Otolin-1 immunohistochemistry staining in the infarct region at day 7 postMI.

Serial sections are stained with Otolin-1 and Eosin to show differential staining in the
Otolin-1 slide. Images are shown at 40x magnification.

A.2

Otolin-1 and echocardiography
Echocardiography data for individual mice at day 0 and day 5 post-MI are

presented in Table A.1. Additionally, regression analysis for comparisons of infarct size
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and ejection fraction to Otolin-1 levels at day 5 post-MI are also provided here and were
not included in the main body of the paper, as no significance is shown between
parameters (Figure A.8).

Table A.1

Echocardiography data and Otolin-1 protein levels for individual animals at
days 0 and 5 post-MI.

Mouse
ID
8844

Day postMI
0

8845

0

8846

0

8847

0

8966

0

8967

0

8974

0

9031

0

7317

5

7318

5

8492

5

8660

5

6918

5

6919

5

6920

5

6921

5

Otolin-1
levels

0.1712
0.0771
0.0539
0.0669
0.0501
0.0432
0.0884
0.0648
0.0000
0.0025
0.0022
0.0019
0.0013
0.0056
0.0039
0.0052

EDD
(mm)
3.71

ESD
(mm)
2.23

FS
(%)
40

EF
(%)
66

Infarct
(%)
0

3.54

2.22

37

64

0

3.35

2.03

39

76

0

3.60

2.37

34

70

0

3.36

2.26

33

66

0

3.33

1.88

44

72

0

3.60

2.37

34

70

0

3.88

2.54

35

66

0

5.80

5.44

6

7

58

5.07

4.36

14

15

34

5.29

4.91

7

9

67

5.39

5.10

5

11

61

5.25

4.96

6

13

58

4.47

4.14

7

8

46

4.52

4.20

7

14

40

4.35

3.92

10

18

40

41

Figure A.8

Comparisons of infarct size (left) and ejection fraction (right) to Otolin-1
levels at day 5 post-MI reveal no correlation between parameters.
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